SMND-309 |
Catalog No.GC37653
One-Click Copy Product Info
|
SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1065559-56-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SMND-309 is a novel derivative of salvianolic acid B, and has shown protective effects against rat cortical neuron damage in vitro and in vivo. IC50 value:Target: SMND-309 mitigated the effects of ischemia and reperfusion injury on brain by decreasing the infract volume, improving neurological function, increasing the survival of neurons and promoting angiogenesis by increasing the levels of erythropoietin (EPO), erythropoietin receptor (EPOR), phosphorylated JAK2 (P-JAK2), phosphorylated STAT3 (P-STAT3), VEGF and VEGF receptor 2 (Flk-1) in the brain.
[1]. Hou J, Tian J, Jiang W, Gao Y, Fu F. Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis. Eur J Pharmacol. 2011 Jan 10;650(1):390-5. [2]. Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J. Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats. Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23. [3]. Tian J, Fu F, Li G, Wang Y, Gao Y, Liu Z, Zhang S. SMND-309, a novel derivate of salvianolic acid B, ameliorates cerebral infarction in rats: characterization and role. Brain Res. 2009 Mar 31;1263:114-21. [4]. Tian J, Li G, Zhang S, Gao Y, Jiang W, Fu F, Liu Z. SMND-309, a novel derivate of salvianolic acid B, attenuates apoptosis and ameliorates mitochondrial energy metabolism in rat cortical neurons. Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):176-84. [5]. Jian Hou et al. Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis European Journal of Pharmacology Volume 650, Issue 1, 10 January 2011, Pages 390-395
| Cas No. | 1065559-56-9 | SDF | |
| Canonical SMILES | OC1=C(C(/C=C/C(O)=O)=CC=C1O)/C(C(O)=O)=C\C2=CC(O)=C(C=C2)O | ||
| Formula | C18H14O8 | M.Wt | 358.3 |
| Solubility | DMSO: ≥ 3.7 mg/mL (10.33 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.791 mL | 13.9548 mL | 27.9096 mL |
| 5 mM | 558.2 μL | 2.791 mL | 5.5819 mL |
| 10 mM | 279.1 μL | 1.3955 mL | 2.791 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)